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Changes in carotid intima-media thickening in
patients with type 2 diabetes mellitus:
Subanalysis of the Sitagliptin Preventive Study
of Intima-Media Thickness Evaluation
Type 2 diabetes mellitus is a risk factor
for cardiovascular disease. Both the abso-
lute value and progression of carotid
artery intima-media thickness (IMT) are
considered a marker of progression of
atherosclerosis. We reported recently that
treatment with sitagliptin, a dipeptidyl
peptidase-4 inhibitor, attenuated the pro-
gression of carotid IMT in insulin-treated
patients with type 2 diabetes mellitus
compared with conventional therapy1.
Here, we compared the efﬁcacy of treat-
ment with sitagliptin with that of other
modalities on the progression of carotid
IMT in prespeciﬁed subgroups of the
Sitagliptin Preventive Study of Intima-
Media Thickness Evaluation (SPIKE) reg-
istered on the University Hospital Medi-
cal Information Network Clinical Trials
Registry (UMIN000007396)1,2. The aim
of the comparison was to identify the
characteristics of patients who beneﬁted
most from the sitagliptin treatment in
terms of decrease in IMT.
The recruits in the original study
included 282 insulin-treated Japanese
type 2 diabetes mellitus patients free of
past history of apparent cardiovascular
disease. They were randomly allocated to
either the sitagliptin group (n = 142) or
the conventional treatment group (using
drugs other than sitagliptin; n = 140).
After the exclusion of eight patients, data
of 137 patients of the sitagliptin group
and 137 of the conventional treatment
group were subjected to analysis. The
mean-IMT of the common carotid arter-
ies (mean-IMT-CCA) and right and left
max-IMT-CCA were measured by expert
sonographers at the start of the study,
and the procedure was repeated after 52
and 104 weeks, as reported previously1,2.
Figure 1 shows differences in treatment-
induced delta change in carotid IMT, rel-
ative to baseline in 243 patients whose
IMT data were available at baseline and
104 weeks, according to various prede-
ﬁned risk factors for atherosclerosis. The
results showed consistent reductions in
mean IMT-CCA and left max IMT-
CCA, but not right max IMT-CCA, in
the sitagliptin group (Figure 1). In partic-
ular, a greater reduction in carotid IMT
was noted after treatment with sitagliptin
in patients with risk factors for cardiovas-
cular disease, such as higher glycated
hemoglobin, higher body mass index,
longer duration of type 2 diabetes melli-
tus, use of angiotensin-converting
enzyme inhibitors/angiotensin II receptor
blocker, use of statins, worse hyperten-
sion and/or hyperlipidemia at baseline,
compared with conventional treatment.
These data suggest that treatment with
dipeptidyl peptidase-4 inhibitors seems to
prevent the progression of carotid
atherosclerosis regardless of disease
burden. Previous studies showed that
treatment with statins and angiotensin-
converting enzyme inhibitors reduces the
progression of carotid atherosclerosis in
patients with type 2 diabetes mellitus3,4.
In this subgroup analysis, sitagliptin still
attenuated the progression of carotid
IMT, even in patients who were receiving
those therapies. Thus, dipeptidyl
peptidase-4 inhibitors seem to have
unique and/or additive anti-atherosclero-
tic effects as add-on therapy to statins
and/or angiotensin-converting enzyme
inhibitors/angiotensin II receptor blockers.
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Figure 1 | Effects of sitagliptin on progression of atherosclerosis. Data are mean (95% confidence interval [CI]). Follow-up group comparisons were
assessed with the Student’s t-test. The prespecified subgroups for analysis included sex (men, n = 144; women, n = 99), age (<65 years, n = 116;
≥65 years, n = 127), body mass index (<25 kg/m2, n = 132; ≥25 kg/m2, n = 111), glycated hemoglobin (<7%, n = 16; ≥7%, n = 227), use of
angiotensin-converting enzyme inhibitors (ACEi)/angiotensin II receptor blocker (ARB); (yes, n = 128; no, n = 115), use of statins (yes, n = 128; no
n = 115), presence (n = 146)/absence (n = 97) of hypertension and presence (n = 154)/absence (n = 89) of hyperlipidemia at baseline. Solid line
indicates overall treatment effect point, and broken lines indicate no effect point. *P < 0.05 vs the conventional treatment group. There were no
significant interactions between treatment group and each category.
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